Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,256 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "HER2-positive" Clear all
Active, not recruiting No phase listed Observational

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

NCT05889988
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Aitkin, Minnesota • Baxter, Minnesota • Brainerd, Minnesota + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 24, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

NCT00263588
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
28
States / cities
San Francisco, California • Vallejo, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jul 24, 2026, 7:10 PM EDT
Completed No phase listed Observational

Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer

NCT05982886
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 24, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

NCT03858972
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Whittier, California • Lakewood, Colorado • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 1 Interventional

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma

NCT02774421
View directory record Official record
Conditions
Posterior Fossa Ependymoma (PFEPN)
Interventions
Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Months to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Recruiting Phase 2 Interventional

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

NCT02491099
View directory record Official record
Conditions
HER2/Neu+ Uterine Serous Carcinoma
Interventions
Afatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
3
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

NCT01754519
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Cribriform Breast Carcinoma, Invasive Ductal Carcinoma, Not Otherwise Specified, Lobular Breast Carcinoma In Situ, Mucinous Breast Carcinoma, Papillary Breast Carcinoma, Progesterone Receptor Positive, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Tubular Breast Carcinoma
Interventions
Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jul 24, 2026, 7:10 PM EDT
Recruiting Phase 1 Interventional

IKS014 in Advanced Solid Tumors That Express HER2

NCT05872295
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Interventions
IKS014
Drug
Lead sponsor
Iksuda Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264
View directory record Official record
Conditions
Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
BG-68501, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat - LBH589
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

NCT01921335
View directory record Official record
Conditions
Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
Interventions
ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jul 24, 2026, 7:10 PM EDT
Not yet recruiting Phase 2 Interventional

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

NCT07191717
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions
Abemaciclib, Biospecimen Collection, Imlunestrant, Questionnaire Administration, Radiologic Imaging Procedure
Drug · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 2 Interventional

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

NCT03324425
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Simvastatin 80mg
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Jul 24, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

NCT01769508
View directory record Official record
Conditions
HER2 Positive Esophagogastric Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 24, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Jul 24, 2026, 7:10 PM EDT
Recruiting Phase 2 Interventional

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

NCT07405476
View directory record Official record
Conditions
Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Zanidatamab, Resection, Patient Observation, Echocardiography Test, Multigated Acquisition Scan, Endoscopic Procedure, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy Procedure, Digital Rectal Examination, Electronic Health Record Review
Biological · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

NCT02115282
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
653
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 461 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Recruiting Phase 2 Interventional

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
22
States / cities
Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 24, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

NCT01526473
View directory record Official record
Conditions
HER2+ Cancer
Interventions
AVX901
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 1 Interventional

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879
View directory record Official record
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 24, 2026, 7:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

NCT02315196
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin, therapeutic conventional surgery, paclitaxel, laboratory biomarker analysis, quality-of-life assessment
Drug · Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2041
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 24, 2026, 7:10 PM EDT
Recruiting Not applicable Interventional

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

NCT06123988
View directory record Official record
Conditions
HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions
Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 24, 2026, 7:10 PM EDT